age, or for height <5th percentile. Bruzzese 2007 [] LGG (6x109 CFU/d). oral rehydration 6 months 38 Moderate or severe Range: 5 - 18 years. Exacerbations, solution disease, pancreatic hospital admissions, insufficiency, one FEV1, changes in body month from last weight. suppressive therapy Pseudomonas. Steinkamp 2000 [] Dietary counseling+ dietary counseling 3 months 36 Weight for-height < >4 years Energy Intake, dietary supplement: only 95% without diabetes Anthropometrics, 1.8 g linoleic acid, mellitus or liver pulmonary function, 0.75 g oleic acid, 0.25 cirrhosis. plasma phospholipid g palmitic acid, 0.2 g FA stearic acid, 0.02 g linolenic acid (per 100 mL). Caramia 2003 [] Oil mixture: 50% placebo 2 months 14 Pancreatic Range: 6 - 15 years. Anthropometrics, oil, 50% soybean oil, insufficiency, puberty status, 8-10% of energy heterozygotes or clinical status, lung intake. homozygotes for function mutation. ΔF508 Keen 2010 [] 2 of FA blends saturated FA 3 months 43 Nonsmoking, severe Range: 7 - 41 years. Nitric oxide (NO) and containing mainly n-3 mutations, clinically exhaled NO, or n-6 FA. stable Pancreatic immunological insufficiency. markers Epifanio 2012 [] Cyproheptadine 12 placebo 12 weeks 25 Weight-age Range: 5 - 18 years. Anthropometrics, mg/d. <85%. energy intake, AE.
age, or for height <5th percentile. Bruzzese 2007 [] LGG (6x109 CFU/d). oral rehydration solution 6 months 38 Moderate or severe disease, pancreatic insufficiency, one month from last suppressive therapy Pseudomonas. Range: 5 - 18 years. Exacerbations, hospital admissions, FEV1, changes in body weight. Steinkamp 2000 [] Dietary counseling+ dietary supplement: 1.8 g linoleic acid, 0.75 g oleic acid, 0.25 g palmitic acid, 0.2 g stearic acid, 0.02 g linolenic acid (per 100 mL). dietary counseling only 3 months 36 Weight for-height < 95% without diabetes mellitus or liver cirrhosis. >4 years Energy Intake, Anthropometrics, pulmonary function, plasma phospholipid FA Caramia 2003 [] Oil mixture: 50% oil, 50% soybean oil, 8-10% of energy intake. placebo 2 months 14 Pancreatic insufficiency, heterozygotes or homozygotes for ΔF508 mutation. Range: 6 - 15 years. Anthropometrics, puberty status, clinical status, lung function Keen 2010 [] 2 of FA blends containing mainly n-3 or n-6 FA. saturated FA 3 months 43 Nonsmoking, severe mutations, clinically stable Pancreatic insufficiency. Range: 7 - 41 years. Nitric oxide (NO) and exhaled NO, immunological markers Epifanio 2012 [] Cyproheptadine 12 mg/d. placebo 12 weeks 25 Weight-age <85%. Range: 5 - 18 years. Anthropometrics, energy intake, AE.